<DOC>
	<DOCNO>NCT01432262</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , immunogenicity 13-Valent Pneumococcal Conjugate Vaccine ( 13vPnC ) give healthy adult older 50 year age n't receive 23-valent pneumococcal polysaccharide vaccine Mexico .</brief_summary>
	<brief_title>13-valent Pneumococcal Conjugate Vaccine Study Adults = &gt; 50 Years Age Mexico</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female old 50 year age Eligibility must determine medical history , physical exam clinical judgment Able complete electronic diary Available duration study Negative pregnancy test subject group 2 age 50 64 year Practice abstinence use reliable birth control age 50 64 year History allergic reaction vaccine Previous vaccination license experimental pneumococcal vaccine S. pneumonia infection within past 5 year investigational product administration Known suspect immunodeficiency receive treatment include cytotoxic agent systemic corticosteroid , serious chronic disorder malignancy cancer Receipt plasma product immunoglobulins within 60 day Bleeding condition diathesis Receipt investigational product within 28 day study entry Other severe acute chronic medical psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>prevention pneumococcal disease</keyword>
</DOC>